Time Gained to Cardiovascular Disease by Intensive Lipid-Lowering Therapy: Results of Individual Placebo-Controlled Trials and Pooled Effects
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Time Gained to Cardiovascular Disease by Intensive Lipid-Lowering Therapy: Results of Individual Placebo-Controlled Trials and Pooled Effects ; volume:24 ; number:6 ; day:14 ; month:8 ; year:2024 ; pages:743-752 ; date:11.2024
American journal of cardiovascular drugs ; 24, Heft 6 (14.8.2024), 743-752, 11.2024
- Creator
-
Bruggen, Folkert H. van
Haas, Esther C. de
Zuidema, Sytse U.
Luijendijk, Hendrika J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40256-024-00668-y
- URN
-
urn:nbn:de:101:1-2501192121379.132749731823
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bruggen, Folkert H. van
- Haas, Esther C. de
- Zuidema, Sytse U.
- Luijendijk, Hendrika J.
- SpringerLink (Online service)
Other Objects (12)
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Nicotinic acid: a lipid-lowering agent with unrealized potential
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Effects of Lipid-Lowering Drugs Upon Fasting-Induced Platelet Aggregation
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Initial non-adherence to lipid-lowering medication: a systematic literature review
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
In vitro study on antioxidant and lipid-lowering activities of tobacco polysaccharides
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Nicotinic acid: a lipid-lowering agent with unrealized potential
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Effects of Lipid-Lowering Drugs Upon Fasting-Induced Platelet Aggregation
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Initial non-adherence to lipid-lowering medication: a systematic literature review
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
In vitro study on antioxidant and lipid-lowering activities of tobacco polysaccharides
Glycaemic Effects of Non-statin Lipid-Lowering Therapies
Lipid-lowering properties of protein-rich mucuna product
Ezetimibe as lipid-lowering therapy for patients receiving HAART
Nicotinic acid: a lipid-lowering agent with unrealized potential
Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Effects of Lipid-Lowering Drugs Upon Fasting-Induced Platelet Aggregation
Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice
Initial non-adherence to lipid-lowering medication: a systematic literature review
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany